Journal of Diabetes Mellitus

Vol.6 No.2(2016), Paper ID 65678, 4 pages

DOI:10.4236/jdm.2016.62013

 

Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

 

Udaya M. Kabadi

 

Broad Lawns Medical Center and Veterans Affairs Medical Center, Des Moines University, Des Moines, USA
University of Iowa, Iowa City, USA

 

Copyright © 2016 Udaya M. Kabadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Kabadi, U. (2016) Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!. Journal of Diabetes Mellitus, 6, 132-135. doi: 10.4236/jdm.2016.62013.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.